Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Decline in CIN2+ in Younger Women after HPV Vaccine

Publish date:: May 4, 2019

Key clinical point: The rates of CIN2+ have declined in younger women since introduction of the HPV vaccine.

Major finding: The rates of vaccine-targeted CIN2+ declined from 52% in 2008 to 30% in 2016 among women aged 18-24 years.

Study details: Analysis of data from the Human Papillomavirus Vaccine Impact Monitoring Program from 2008 to 2016.

Disclosures: One author declared personal fees from Merck during the course of the study. No other conflicts of interest were declared.

Citation:

McClung N et al. MMWR. 2019 Apr 19;68:337-43.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,